NCT02423200View on ClinicalTrials.gov

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

VX-745

Orally-active P38 MAP kinase alpha-selective inhibitor

Trial Locations (1)

91206

Parexel International, Glendale

Sponsors

Lead Sponsor

EIP Pharma Inc
All Listed Sponsors
lead

EIP Pharma Inc

INDUSTRY